Specimens and Genetic Data. Any and all biological materials and samples, such as blood or tissue, from a Trial Participant collected pursuant to the Protocol (“Specimens”) as well as RNA, DNA, and protein sequence, restriction fragment length polymorphism (RFLP), and similar data collected pursuant to the Protocol (“Genetic Data”) shall be solely owned by Sponsor. Any use of Genetic Data and/or Specimens, whether such use occurs as part of or outside of the Trial will be in accordance with the Protocol, other written instruction, the informed consent form, and Applicable Law. Sponsor grants Institution access to Specimens and Genetic Data only for purposes of the Trial. Institution and Investigator shall deliver all Specimens and Genetic Data to Sponsor or its respective designee in a timely manner throughout the performance of the Trial, as provided in the Protocol, in no event later than sixty (60) days following the completion of the Trial by Institution and Investigator or the earlier termination of this Agreement.

Specimens and Genetic Data. Sponsor shall have the exclusive right and license to use any and all biological materials

Specimens and Genetic Data. Sponsor shall have the exclusive right and license to use any and all biological materials and samples, such as blood or tissue, from a Trial Participant collected pursuant to the Protocol (“Specimens”) as well as RNA, DNA, and protein sequence, restriction fragment length polymorphism (RFLP), and similar data collected pursuant to the Protocol (“Genetic Data”). Any use of Genetic Data and/or Specimens, whether such use occurs as part of or outside of the Trial will be in accordance with the Protocol, other written instruction, the informed consent form, and Applicable Law. Sponsor grants Institution access to Specimens and Genetic Data only for purposes of the Trial. Institution and Investigator shall deliver all Specimens 6.5 Vzorky a genetická data. Zadavatel bude mít výhradní právo a licenci užívat veškeré biologické materiály a vzorky Subjektů hodnocení, například krev nebo tkáně, shromážděné dle Protokolu (dále jen „Vzorky“), jakož i RNA, DNA a proteinové sekvence, polymorfismus délky restrikčních fragmentů (RFLP) a podobné údaje shromážděné dle Protokolu (dále jen „Genetická data“). Veškeré užívání Genetických dat a/nebo Vzorků v rámci nebo mimo rámec Klinické hodnocení musí být vždy v souladu s Protokolem, jinými písemnými pokyny, s formulářem informovaného souhlasu a s Příslušnými právními předpisy. Zadavatel povoluje Zdravotnickému zařízení přístup ke Vzorkům a Genetickým datům pouze and Genetic Data to Sponsor or its respective designee in a timely manner throughout the performance of the Trial, as provided in the Protocol, in no event later than sixty (60) days following the completion of the Trial by Institution and Investigator or the earlier termination of this Agreement. pro účely Klinického hodnocení. Zdravotnické zařízení a Zkoušející budou předávat Zadavateli nebo jím ustanovené osobě všechny Vzorky a Genetická data během celé doby provádění Klinického hodnocení včas, jak je stanoveno v Protokolu, ale v každém případě nejpozději šedesát

Related to Specimens and Genetic Data

Regulatory Materials (a) On a Program-by-Program basis, commencing on the Effective Date until the Regulatory Transfer Date, Prothena shall have the right, in consultation with Celgene, to prepare, file and maintain all Regulatory Materials (including any Regulatory Approvals) necessary for the Development and Manufacture of any Collaboration Candidates and Collaboration Products for such Program (collectively, the “Program Regulatory Materials”), and to interact with Regulatory Authorities in connection with the Development and Manufacture of any Collaboration Candidates and Collaboration Products for such Program. Prothena will provide Celgene with a reasonable opportunity to comment substantively on all material Regulatory Materials prior to filing or taking material action, and will reasonably and in good faith consider any comments and actions recommended by Celgene, including with respect to filing strategy. In addition, Prothena will allow Celgene or its representative to attend any and all meetings with Regulatory Authorities to the extent such attendance is not prohibited or limited by such Regulatory Authority. (b) If Celgene exercises its Phase 1 Portion Participation Right for a given Program, then immediately after such exercise, Prothena shall initiate the transfer of all Program Regulatory Materials, including for clarity any IND for the relevant Collaboration Candidates and/or Collaboration Products that are the subject of such Program to Celgene. The date on which such Program Regulatory Materials are transferred to Celgene shall be the “Regulatory Transfer Date” for such Program. Thereafter, Celgene shall have the right, in consultation with Prothena, to prepare, file, and maintain such Program Regulatory Materials, and to interact with Regulatory Authorities in connection with the Development and, as applicable, Manufacture of such Collaboration Candidates and Collaboration Products for such Program in accordance with the terms and conditions of Section 2.5. Additionally, with respect to any Phase 1 Clinical Trial conducted by Celgene pursuant to Section 2.5, Celgene will provide Prothena with a reasonable opportunity to comment substantively on all material Program Regulatory Materials prior to filing or taking material action, and will reasonably and in good faith consider any comments and actions recommended by Prothena, including with respect to filing strategy. In addition, with respect to any Phase 1 Clinical Trial conducted by Celgene pursuant to Section 2.5, Celgene will allow Prothena or its representative to attend any and all meetings with Regulatory Authorities to the extent such attendance is not prohibited or limited by such Regulatory Authority. For clarity, if the Regulatory Transfer Date does not occur prior to the expiration of the Option Term for such Program, Section 2.6.1(a) (and not this Section 2.6.1(b)) shall apply.
Operator Materials Operator retains all right, title and interest in and to any and all of Operator’s software, materials, tools, forms, documentation, training and implementation materials and intellectual property (“Operator Materials”). Operator grants to the LEA a personal, nonexclusive license to use the Operator Materials for its own non-commercial, incidental use as set forth in the Service Agreement. Operator represents that it has all intellectual property rights necessary to enter into and perform its obligations in this DPA and the Service Agreement, warrants to the District that the District will have use of any intellectual property contemplated by the Service Agreement free and clear of claims of any nature by any third Party including, without limitation, copyright or patent infringement claims, and agrees to indemnify the District for any related claims.
Immunizations (except for those preventive immunizations for routine use in children, adolescents, and adults that have in effect a recommendation from the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention);
Customer Materials Subject to Section 4(a), all right, title and interest (including all Intellectual Property Rights) in and to the Customer Materials are owned by Customer or Customer’s suppliers.
Background Screening VENDOR shall comply with all requirements of Sections 1012.32 and 1012.465, Florida Statutes, and all of its personnel who (1) are to be permitted access to school grounds when students are present, (2) will have direct contact with students, or (3) have access or control of school funds, will successfully complete the background screening required by the referenced statutes and meet the standards established by the statutes. This background screening will be conducted by SBBC in advance of VENDOR or its personnel providing any services under the conditions described in the previous sentence. VENDOR shall bear the cost of acquiring the background screening required by Section 1012.32, Florida Statutes, and any fee imposed by the Florida Department of Law Enforcement to maintain the fingerprints provided with respect to VENDOR and its personnel. The parties agree that the failure of VENDOR to perform any of the duties described in this section shall constitute a material breach of this Agreement entitling SBBC to terminate immediately with no further responsibilities or duties to perform under this Agreement. VENDOR agrees to indemnify and hold harmless SBBC, its officers and employees from any liability in the form of physical or mental injury, death or property damage resulting from VENDOR’s failure to comply with the requirements of this section or with Sections 1012.32 and 1012.465, Florida Statutes.
Third Party Materials The Application may display, include, or make available third-party content (including data, information, applications, and other products, services, and/or materials) or provide links to third-party websites or services, including through third- party advertising ("Third-Party Materials"). You acknowledge and agree that Company is not responsible for Third-Party Materials, including their accuracy, completeness, timeliness, validity, copyright compliance, legality, decency, quality, or any other aspect thereof. Company does not assume and will not have any liability or responsibility to you or any other person or entity for any Third-Party Materials. Third-Party Materials and links thereto are provided solely as a convenience to you, and you access and use them entirely at your own risk and subject to such third parties' terms and conditions.
Technical Information The Employer agrees to provide to the Union such information that is available relating to employees in the bargaining unit, as may be required by the Union for collective bargaining purposes.
PROGENY Unmodified descendant from the MATERIAL, such as virus from virus, cell from cell, or organism from organism.
Immunization The following immunizations are recommended by the BSA. Tetanus immunization is required and must have been received within the last 10 years. If you had the disease, check the disease column and list the date. If immunized, check yes and provide the year received.
Vaccination and Inoculation ‌ (a) The Employer agrees to take all reasonable precautions to limit the spread of infectious diseases among employees, including in-service seminars for employees. Where the Employer or Occupational Health and Safety Committee identifies high risk areas which expose employees to infectious or communicable diseases for which there are protective immunizations available, such immunizations shall be provided at no cost to the employee. The Committee may consult with the Medical Health Officer. Where the Medical Health Officer identifies such a risk, the immunization shall also be provided at no cost. The Employer shall provide Hepatitis B vaccine, free of charge, to those employees who may be exposed to bodily fluids or other sources of infection. (b) An employee may be required by the Employer, at the request of and at the expense of the Employer, to take a medical examination by a physician of the employee's choice. Employees may be required to take skin tests, x-ray examination, vaccination, and other immunization (with the exception of a rubella vaccination when the employee is of the opinion that a pregnancy is possible), unless the employee's physician has advised in writing that such a procedure may have an adverse effect on the employee's health.

Specimens and Genetic Data Sample Clauses

Filter & Search

Related Clauses

Parent Clauses

Related to Specimens and Genetic Data